Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | SLC5A1 | P13866 | 4/20 | 0.63 |
| ▸ | SLC5A2 | P31639 | 4/20 | 0.63 |
| ▸ | MEN1 | O00255 | 4/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | HPGD | P15428 | 3/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 5/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.61 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1224101 | 0.91 | SLC5A1 (0.75) | LMNASLC5A1SLC5A2MEN1KMT2A | |
| SCHEMBL13991130 | 0.86 | LMNA (0.79) | LMNASLC5A1SLC5A2MEN1KMT2A | |
| SCHEMBL3408972 | 0.84 | NFKB1 (0.61) | LMNASLC5A1SLC5A2MEN1KMT2A | |
| SCHEMBL29585688 | 0.83 | LMNA (0.74) | LMNASLC5A1SLC5A2MEN1KMT2A | |
| SCHEMBL11566548 | 0.82 | LMNA (1.00) | LMNASLC5A1SLC5A2MEN1KMT2A | |
| SCHEMBL5622859 | 0.81 | NFKB1 (0.62) | LMNASLC5A1SLC5A2MEN1KMT2A | |
| SCHEMBL5623783 | 0.80 | NFKB1 (0.61) | LMNASLC5A1SLC5A2MEN1KMT2A | |
| SCHEMBL457127 | 0.78 | SLC5A1 (1.00) | LMNASLC5A1SLC5A2MEN1KMT2A | |
| SCHEMBL11628971 | 0.77 | SLC5A1 (0.71) | LMNASLC5A1SLC5A2MEN1KMT2A | |
| Ononetin SCHEMBL2948430 | 0.77 | NPC1 (1.00) | LMNASLC5A1SLC5A2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816331-B2 | Substituted indazole-O-glucosides | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-19 | — | — | US | disclosed |
| US-20100062971-A1 | SUBSTITUTED INDAZOLE-O-GLUCOSIDES | PATEL MONA | 2010-03-11 | — | — | US | disclosed |
| EP-1680414-A4 | SUBSTITUTED INDAZOLE-O-GLUCOSIDES | JANSSEN PHARMACEUTICA NV (BE) | 2009-05-27 | — | — | EP | disclosed |
| US-20090099104-A1 | SUBSTITUTED INDAZOLES-O- GLUCOSIDES | PATEL MONA | 2009-04-16 | — | — | US | disclosed |
| US-7511021-B2 | Substituted indazole-O-glucosides | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-31 | — | — | US | disclosed |
| US-20060217323-A1 | Substituted indazole-O-glucosides | Tanabe Pharma Corporation (JP) | 2006-09-28 | — | — | US | disclosed |
| US-7084124-B2 | Substituted indazole-O-glucosides | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-08-01 | — | — | US | disclosed |
| EP-1680414-A2 | SUBSTITUTED INDAZOLE-O-GLUCOSIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-19 | — | — | EP | disclosed |
| US-20050032711-A1 | Substituted indazole-O-glucosides | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-10 | — | — | US | disclosed |
| WO-2005011592-A2 | SUBSTITUTED INDAZOLE-O-GLUCOSIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032711-A1 | Substituted indazole-O-glucosides | GYS2, GPR119, UGGT1 | LMNA 2159/4885SLC5A1 9/4885SLC5A2 10/4885 |
| US-20100062971-A1 | SUBSTITUTED INDAZOLE-O-GLUCOSIDES | GYS2, GPR119, UGGT1 | LMNA 2159/4885SLC5A1 9/4885SLC5A2 10/4885 |
| US-20090099104-A1 | SUBSTITUTED INDAZOLES-O- GLUCOSIDES | GYS2, GPR119, PYGL | LMNA 1835/4885SLC5A1 11/4885SLC5A2 10/4885 |
| US-20060217323-A1 | Substituted indazole-O-glucosides | GYS2, GPR119, UGGT1 | LMNA 2159/4885SLC5A1 9/4885SLC5A2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.